2016 Q4 Form 10-K Financial Statement

#000114420418013354 Filed on March 07, 2018

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2016 Q2
Revenue $3.336M $3.098M $2.828M
YoY Change 13.79% 16.13% 22.57%
Cost Of Revenue $3.560M $3.280M $2.969M
YoY Change 21.92% 11.23% 14.16%
Gross Profit -$227.8K -$184.6K -$140.9K
YoY Change -2210.37% -34.4% -51.99%
Gross Profit Margin -6.83% -5.96% -4.98%
Selling, General & Admin $1.740M $1.510M $1.973M
YoY Change -13.43% -14.38% 24.25%
% of Gross Profit
Research & Development $540.0K $690.0K $509.9K
YoY Change -16.92% 30.29% 79.81%
% of Gross Profit
Depreciation & Amortization $220.0K $210.0K $81.07K
YoY Change 10.0% 157.04% 3.1%
% of Gross Profit
Operating Expenses $2.510M $2.411M $2.690M
YoY Change -11.62% -2.62% 30.59%
Operating Profit -$2.733M -$2.596M -$2.831M
YoY Change -3.44% -5.52% 20.63%
Interest Expense -$10.00K -$80.00K $9.322K
YoY Change -50.0% -1019.33% -32.22%
% of Operating Profit
Other Income/Expense, Net -$30.00K -$84.18K -$71.52K
YoY Change 1958.6% -106.72%
Pretax Income -$2.750M -$2.680M -$2.902M
YoY Change -3.85% -2.9% 125.22%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.747M -$2.680M -$2.902M
YoY Change -4.12% -2.96% 125.22%
Net Earnings / Revenue -82.34% -86.52% -102.64%
Basic Earnings Per Share
Diluted Earnings Per Share -$30.94K -$33.34K -$38.15K
COMMON SHARES
Basic Shares Outstanding 90.70M shares 80.39M shares 76.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.47M $5.190M $2.840M
YoY Change 258.24% -23.0% -65.37%
Cash & Equivalents $13.47M
Short-Term Investments
Other Short-Term Assets $200.0K $410.0K $720.0K
YoY Change -71.83% -14.58% 56.52%
Inventory $3.093M $3.050M $3.147M
Prepaid Expenses
Receivables $40.99K $20.00K $105.7K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $16.80M $8.670M $6.811M
YoY Change 132.4% -12.16% -43.85%
LONG-TERM ASSETS
Property, Plant & Equipment $2.435M $2.450M $2.415M
YoY Change -4.74% -7.44% -11.09%
Goodwill
YoY Change
Intangibles $7.390M $7.385M
YoY Change 0.35% 2.49%
Long-Term Investments $1.020M $1.050M $1.081M
YoY Change -16.55% -11.76% -12.15%
Other Assets
YoY Change
Total Long-Term Assets $10.84M $10.90M $10.88M
YoY Change -2.02% -2.21% -2.4%
TOTAL ASSETS
Total Short-Term Assets $16.80M $8.670M $6.811M
Total Long-Term Assets $10.84M $10.90M $10.88M
Total Assets $27.64M $19.57M $17.69M
YoY Change 51.08% -6.88% -24.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.340M $1.380M $1.567M
YoY Change 4.43% 11.4% 59.18%
Accrued Expenses $1.600M $1.280M $1.191M
YoY Change 18.57% 27.33% 3.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $310.0K $330.0K $320.0K
YoY Change 0.0% 0.0% -3.03%
Total Short-Term Liabilities $3.249M $2.990M $3.305M
YoY Change 2.76% -3.14% 12.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $310.0K $310.0K
YoY Change -100.0% -50.0% -49.18%
Other Long-Term Liabilities $60.00K $100.0K $120.0K
YoY Change -98.06% -96.77% -96.23%
Total Long-Term Liabilities $60.00K $410.0K $430.0K
YoY Change -98.24% -88.98% -88.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.249M $2.990M $3.305M
Total Long-Term Liabilities $60.00K $410.0K $430.0K
Total Liabilities $3.308M $3.400M $3.729M
YoY Change -49.63% -50.0% -44.42%
SHAREHOLDERS EQUITY
Retained Earnings -$78.14M -$72.71M
YoY Change 17.4% 19.34%
Common Stock $907.00 $760.00
YoY Change 27.75% 7.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.33M $16.17M $13.96M
YoY Change
Total Liabilities & Shareholders Equity $27.64M $19.57M $17.69M
YoY Change 51.08% -6.88% -24.0%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2016 Q2
OPERATING ACTIVITIES
Net Income -$2.747M -$2.680M -$2.902M
YoY Change -4.12% -2.96% 125.22%
Depreciation, Depletion And Amortization $220.0K $210.0K $81.07K
YoY Change 10.0% 157.04% 3.1%
Cash From Operating Activities -$1.910M -$2.090M -$3.090M
YoY Change -22.36% 65.87% 186.11%
INVESTING ACTIVITIES
Capital Expenditures -$310.0K -$140.0K -$100.0K
YoY Change 181.82% -30.0% -28.57%
Acquisitions
YoY Change
Other Investing Activities $130.0K -$110.0K -$20.00K
YoY Change
Cash From Investing Activities -$190.0K -$240.0K -$120.0K
YoY Change 72.73% 20.0% -14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.38M 4.680M 0.000
YoY Change -2631.71% -100.0%
NET CHANGE
Cash From Operating Activities -1.910M -2.090M -3.090M
Cash From Investing Activities -190.0K -240.0K -120.0K
Cash From Financing Activities 10.38M 4.680M 0.000
Net Change In Cash 8.280M 2.350M -3.210M
YoY Change -377.85% -260.96% -173.79%
FREE CASH FLOW
Cash From Operating Activities -$1.910M -$2.090M -$3.090M
Capital Expenditures -$310.0K -$140.0K -$100.0K
Free Cash Flow -$1.600M -$1.950M -$2.990M
YoY Change -31.91% 83.96% 218.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-15130 USD
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q2 dei Entity Public Float
EntityPublicFloat
158400000 USD
CY2017 dei Trading Symbol
TradingSymbol
XXII
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124136087 shares
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
746805 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
195569 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2434663 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7389946 USD
CY2017Q4 xxii Assests Noncurrent Excluding Property Plant And Equipment Net
AssestsNoncurrentExcludingPropertyPlantAndEquipmentNet
8801904 USD
CY2017Q4 us-gaap Assets
Assets
79739406 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1987675 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4313206 USD
CY2017Q4 us-gaap Liabilities
Liabilities
4313206 USD
CY2016Q4 us-gaap Liabilities
Liabilities
3307998 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1236 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
166592536 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102471907 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91167572 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78138455 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
75426200 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
24334359 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79739406 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27642357 USD
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
307938 USD
CY2017Q4 xxii Accrued Severance Liabilities Current
AccruedSeveranceLiabilitiesCurrent
0 USD
CY2016Q4 xxii Accrued Severance Liabilities Current
AccruedSeveranceLiabilitiesCurrent
199657 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
957066 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40992 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
67621455 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
16797435 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28350 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12279979 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-11387847 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-13299864 USD
CY2016 xxii Gain Loss From Warrant Liability
GainLossFromWarrantLiability
29615 USD
CY2017 xxii Gain Loss From Warrant Liability
GainLossFromWarrantLiability
-157809 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-11581430 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-13029117 USD
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79842773 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101161380 shares
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7116535 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6193269 USD
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1161952 USD
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1581741 USD
CY2017 us-gaap Depreciation
Depreciation
353435 USD
CY2016 us-gaap Depreciation
Depreciation
326124 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13029117 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11581430 USD
CY2017 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
593562 USD
CY2016 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
516056 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Interest Expense
InterestExpense
29104 USD
CY2016 us-gaap Interest Expense
InterestExpense
37745 USD
CY2017 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
115098 USD
CY2016 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
16885 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8521998 USD
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9102560 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-12043883 USD
CY2015 xxii Gain Loss From Warrant Liability
GainLossFromWarrantLiability
144550 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-11031931 USD
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68143284 shares
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7760127 USD
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1357518 USD
CY2015 us-gaap Depreciation
Depreciation
319699 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11031931 USD
CY2015 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
454612 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Interest Expense
InterestExpense
52982 USD
CY2015 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
31198 USD
CY2016 xxii Amortization Of License Fees
AmortizationOfLicenseFees
98022 USD
CY2017 xxii Amortization Of License Fees
AmortizationOfLicenseFees
98022 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
880509 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
941650 USD
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
30873 USD
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
531356 USD
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
129228 USD
CY2016 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-497856 USD
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
551236 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-136297 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
473804 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-21965 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
586109 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9887580 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12068383 USD
CY2016 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
197229 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-553770 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60586245 USD
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
196 USD
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12447108 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20149241 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62845974 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
906074 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10238 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9808654 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9707891 USD
CY2017 xxii Increase Decrease In Accrued Severance
IncreaseDecreaseInAccruedSeverance
-203365 USD
CY2016 xxii Increase Decrease In Accrued Severance
IncreaseDecreaseInAccruedSeverance
-233655 USD
CY2017 us-gaap Accretion Expense
AccretionExpense
29104 USD
CY2016 us-gaap Accretion Expense
AccretionExpense
37745 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
848974 USD
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744157 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3659534 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13468188 USD
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
450208 USD
CY2016 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
356541 USD
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-10000 USD
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2017 us-gaap Interest Paid Net
InterestPaidNet
29104 USD
CY2016 us-gaap Interest Paid Net
InterestPaidNet
37745 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2017 xxii Patent And Trademark Additions Included In Accounts Payable
PatentAndTrademarkAdditionsIncludedInAccountsPayable
188818 USD
CY2016 xxii Patent And Trademark Additions Included In Accounts Payable
PatentAndTrademarkAdditionsIncludedInAccountsPayable
185341 USD
CY2017 xxii Inventory Reserve Adjustments
InventoryReserveAdjustments
60623 USD
CY2016 xxii Inventory Reserve Adjustments
InventoryReserveAdjustments
-145000 USD
CY2016 xxii Reclassification Of Warrants Liability To Capital In Excess Of Par Value
ReclassificationOfWarrantsLiabilityToCapitalInExcessOfParValue
2810000 USD
CY2017 xxii Reclassification Of Warrants Liability To Capital In Excess Of Par Value
ReclassificationOfWarrantsLiabilityToCapitalInExcessOfParValue
0 USD
CY2017 xxii Machinery And Equipment Additions Included In Accounts Payable
MachineryAndEquipmentAdditionsIncludedInAccountsPayable
77913 USD
CY2016 xxii Machinery And Equipment Additions Included In Accounts Payable
MachineryAndEquipmentAdditionsIncludedInAccountsPayable
7765 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
28350 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2015 xxii Amortization Of License Fees
AmortizationOfLicenseFees
98022 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1326393 USD
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2259147 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
701534 USD
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
478955 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
86332 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7321811 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-450661 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50688 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5130082 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
61230 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2642390 USD
CY2015 xxii Increase Decrease In Accrued Severance
IncreaseDecreaseInAccruedSeverance
-225000 USD
CY2015 us-gaap Accretion Expense
AccretionExpense
45121 USD
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
676289 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6402687 USD
CY2015 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
413180 USD
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000 USD
CY2015 us-gaap Interest Paid Net
InterestPaidNet
7600 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2015 xxii Patent And Trademark Additions Included In Accounts Payable
PatentAndTrademarkAdditionsIncludedInAccountsPayable
310078 USD
CY2015 xxii Reclassification Of Warrants Liability To Capital In Excess Of Par Value
ReclassificationOfWarrantsLiabilityToCapitalInExcessOfParValue
0 USD
CY2015 xxii Machinery And Equipment Additions Included In Accounts Payable
MachineryAndEquipmentAdditionsIncludedInAccountsPayable
2525 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
10000 USD
CY2017Q4 xxii Inventory Tobacco Leaf Gross
InventoryTobaccoLeafGross
1552474 USD
CY2016Q4 xxii Inventory Tobacco Leaf Gross
InventoryTobaccoLeafGross
1936039 USD
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
195000 USD
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
255623 USD
CY2017Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
289004 USD
CY2016Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
340523 USD
CY2017Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1636059 USD
CY2016Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1071747 USD
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
593562 USD
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
516056 USD
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
454612 USD
CY2017 us-gaap Excise And Sales Taxes
ExciseAndSalesTaxes
8533000 USD
CY2016 us-gaap Excise And Sales Taxes
ExciseAndSalesTaxes
7452000 USD
CY2015 us-gaap Excise And Sales Taxes
ExciseAndSalesTaxes
5703000 USD
CY2017 us-gaap Advertising Expense
AdvertisingExpense
75000 USD
CY2016 us-gaap Advertising Expense
AdvertisingExpense
325000 USD
CY2015 us-gaap Advertising Expense
AdvertisingExpense
229000 USD
CY2016Q1 xxii Warrant Exercisable Per Share
WarrantExercisablePerShare
3.36
CY2016Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2810000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1235373 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
881938 USD
CY2014 xxii Finite Lived Intangible Assets Acquired With Notes Payable
FiniteLivedIntangibleAssetsAcquiredWithNotesPayable
925730 USD
CY2014Q4 us-gaap Other Commitment
OtherCommitment
1213000 USD
CY2014Q4 us-gaap Severance Costs1
SeveranceCosts1
624320 USD
CY2014Q4 xxii Severance Term
SeveranceTerm
P36M
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
157809 USD
CY2016 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
29615 USD
CY2017 xxii Warrants With Provision Of Anti Dilution
WarrantsWithProvisionOfAntiDilution
94721 shares
CY2017 xxii Warrants Without Provision Of Anti Dilution
WarrantsWithoutProvisionOfAntiDilution
11993359 shares
CY2016 xxii Number Of Warrants Exercised
NumberOfWarrantsExercised
67042 shares
CY2016 xxii Number Of Warrants Expired
NumberOfWarrantsExpired
6831115 shares
CY2016 xxii Unexercisable Warrants
UnexercisableWarrants
2000000 shares
CY2017Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
225000 USD
CY2017 xxii Milestone Payment
MilestonePayment
150000 USD
CY2017Q4 xxii Minimum Annual Royalties After Year Four
MinimumAnnualRoyaltiesAfterYearFour
50000 USD
CY2017Q4 xxii Minimum Annua Lroyalties In Year Two
MinimumAnnuaLroyaltiesInYearTwo
15000 USD
CY2017Q4 xxii Minimum Annual Royalties In Year Three
MinimumAnnualRoyaltiesInYearThree
25000 USD
CY2017Q4 xxii Minimum Annual Royalties In Year One
MinimumAnnualRoyaltiesInYearOne
10000 USD
CY2017Q1 us-gaap License Costs
LicenseCosts
85681 USD
CY2014Q3 xxii License Maintenance Fees Due Current
LicenseMaintenanceFeesDueCurrent
75000 USD
CY2017 xxii Lease Payments
LeasePayments
156000 USD
CY2016 xxii Lease Payments
LeasePayments
146000 USD
CY2015 xxii Lease Payments
LeasePayments
127000 USD
CY2016Q2 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
1471 USD
CY2017Q1 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
1219 USD
CY2016Q2 xxii Litigation Settlement Shares To Be Issued
LitigationSettlementSharesToBeIssued
2077555 shares
CY2016Q2 xxii Litigation Settlement Shares To Be Issued
LitigationSettlementSharesToBeIssued
2077555 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101161380 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79842773 shares
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3886000 USD
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0205 pure
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0131 pure
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9 pure
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y6M22D
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y10M13D
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.66
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1242110 USD
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
58975513 USD
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
3282537 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
3092686 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
1366493 USD
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
1020313 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
216490 USD
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
58681 USD
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
12591952 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
10958148 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
11463321 USD
CY2017 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2016 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2015 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1000000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
270747 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-193583 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1011952 USD
CY2017 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-3618 USD
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 USD
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 USD
CY2017 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
346180 USD
CY2016 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-202338 USD
CY2015 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-95684 USD
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90698113 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90698113 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123569367 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123569367 shares
CY2017Q4 xxii Inventorytobacco Leaf Net
InventorytobaccoLeafNet
3477537 USD
CY2016Q4 xxii Inventorytobacco Leaf Net
InventorytobaccoLeafNet
3348309 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
15219737 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
11728500 USD
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
34500 USD
CY2015 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
325000 USD
CY2015 xxii Stock Issued During Period Value Warrants Exercise
StockIssuedDuringPeriodValueWarrantsExercise
50688 USD
CY2016 xxii Stock Issued During Period Value Warrants Exercise
StockIssuedDuringPeriodValueWarrantsExercise
196 USD
CY2017 xxii Stock Issued During Period Value Warrants Exercise
StockIssuedDuringPeriodValueWarrantsExercise
12447108 USD
CY2017 xxii Common Stock Issues During Period Value Private Placement
CommonStockIssuesDuringPeriodValuePrivatePlacement
50732200 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5576083 USD
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1623423 USD
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
894715 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
941650 USD
CY2016 xxii Common Stock Issued During Period Value Registered Direct Offering One
CommonStockIssuedDuringPeriodValueRegisteredDirectOfferingOne
5091791 USD
CY2016 xxii Common Stock Issued During Period Value Registered Direct Offering Two
CommonStockIssuedDuringPeriodValueRegisteredDirectOfferingTwo
4682764 USD
CY2016 xxii Common Stock Issued During Period Value Registered Direct Offering Three
CommonStockIssuedDuringPeriodValueRegisteredDirectOfferingThree
10707823 USD
CY2016 xxii Reclassification Of Warrant Liability To Capital In Excess Of Par
ReclassificationOfWarrantLiabilityToCapitalInExcessOfPar
2810000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2017 us-gaap Gain Loss On Investments
GainLossOnInvestments
346180 USD
CY2016 us-gaap Gain Loss On Investments
GainLossOnInvestments
-202338 USD
CY2015 us-gaap Gain Loss On Investments
GainLossOnInvestments
-95684 USD
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15130 USD
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
58979131 USD
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2017 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
0 USD
CY2016 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
0 USD
CY2015 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
174925 USD
CY2017 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-333334 USD
CY2016 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-333333 USD
CY2015 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-333333 USD
CY2017 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
0 USD
CY2016 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
0 USD
CY2015 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
34500 USD
CY2017 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
CY2016 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
CY2015 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
46069 USD
CY2017 xxii Proceeds From Issuance Registered Direct Offering Two
ProceedsFromIssuanceRegisteredDirectOfferingTwo
0 USD
CY2016 xxii Proceeds From Issuance Registered Direct Offering Two
ProceedsFromIssuanceRegisteredDirectOfferingTwo
10707823 USD
CY2015 xxii Proceeds From Issuance Registered Direct Offering Two
ProceedsFromIssuanceRegisteredDirectOfferingTwo
0 USD
CY2017 xxii Proceeds From Issuance Registered Direct Offering One
ProceedsFromIssuanceRegisteredDirectOfferingOne
50732200 USD
CY2016 xxii Proceeds From Issuance Registered Direct Offering One
ProceedsFromIssuanceRegisteredDirectOfferingOne
0 USD
CY2015 xxii Proceeds From Issuance Registered Direct Offering One
ProceedsFromIssuanceRegisteredDirectOfferingOne
0 USD
CY2017 xxii Patent And Trademark Additions Included In Accrued Expenses
PatentAndTrademarkAdditionsIncludedInAccruedExpenses
0 USD
CY2016 xxii Patent And Trademark Additions Included In Accrued Expenses
PatentAndTrademarkAdditionsIncludedInAccruedExpenses
0 USD
CY2015 xxii Patent And Trademark Additions Included In Accrued Expenses
PatentAndTrademarkAdditionsIncludedInAccruedExpenses
17715 USD
CY2017 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2016 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2017Q1 us-gaap Revenues
Revenues
2231517 USD
CY2017Q2 us-gaap Revenues
Revenues
3897206 USD
CY2017Q3 us-gaap Revenues
Revenues
4530865 USD
CY2017Q4 us-gaap Revenues
Revenues
5940656 USD
CY2017Q1 us-gaap Gross Profit
GrossProfit
-273897 USD
CY2017Q2 us-gaap Gross Profit
GrossProfit
-165055 USD
CY2017Q3 us-gaap Gross Profit
GrossProfit
-340369 USD
CY2017Q4 us-gaap Gross Profit
GrossProfit
71409 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2969949 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3282525 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3274081 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3773309 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2621277 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3355624 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3316634 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-3735582 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2016Q1 us-gaap Revenues
Revenues
3019056 USD
CY2016Q2 us-gaap Revenues
Revenues
2827658 USD
CY2016Q3 us-gaap Revenues
Revenues
3097648 USD
CY2016Q4 us-gaap Revenues
Revenues
3335617 USD
CY2016Q1 us-gaap Gross Profit
GrossProfit
123646 USD
CY2016Q2 us-gaap Gross Profit
GrossProfit
-140913 USD
CY2016Q3 us-gaap Gross Profit
GrossProfit
-184618 USD
CY2016Q4 us-gaap Gross Profit
GrossProfit
-227814 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3228404 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2830830 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2595812 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2732801 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3252452 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2902354 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-2679988 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-2746636 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017 xxii June Two Thousand Seventeen Warrant Exercise Agreements Disclosure
JuneTwoThousandSeventeenWarrantExerciseAgreementsDisclosure
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>NOTE 3. &#150; JUNE 2017 WARRANT EXERCISE AGREEMENTS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On June 19, 2017, the Company entered into Warrant Exercise Agreements (the &#8220;Agreements&#8221;) with all the holders (the &#8220;Holders&#8221;) of outstanding warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,043,211</font> shares of common stock of the Company at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share and warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,250,000</font> shares of common stock of the Company at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.45</font> per share (collectively, the &#8220;Warrants&#8221;). These Warrants to purchase shares of the Company&#8217;s common stock were acquired by the Holders in registered direct offerings in October of 2016 and in July of 2016, respectively, as more fully described in Notes 4 and 5 below. The Company and the Holders agreed that the Holders would, subject to beneficial ownership limitations on exercise contained in the Warrants, exercise all the Warrants for cash. In June 2017, the Holders exercised <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,229,711</font> Warrants at $1.00 per share and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,354,948</font> Warrants at $1.45 per share, resulting in net proceeds to the Company in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,169,212</font>, after deducting expenses associated with the transaction. In July and August of 2017, the Holders exercised <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,813,500</font> Warrants at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,895,052</font> Warrants at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.45</font> per share, resulting in net proceeds to the Company in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,167,646</font>, after deducting expenses associated with the transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In consideration for the Holders exercising their Warrants for cash, the Company issued to each Holder a new warrant (the &#8220;New Warrants&#8221;) to purchase shares of common stock of the Company equal to the number of shares of common stock received by each Holder upon the cash exercise of the Holder&#8217;s Warrants. The terms of the New Warrants are substantially similar to the terms of the Warrants exercised, except the New Warrants (i) have an exercise price equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.15</font> per share and (ii) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">are exercisable six months from the date of issuance of the New Warrants for a period of five (5) years.</font> Accordingly, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,293,211</font> New Warrants to the Holders, upon exercise of the Holder&#8217;s Warrants as described above. The New Warrants had a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,049,031</font> at issuance and have been recorded as an adjustment to capital in excess of par.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
2403045 USD
CY2015 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
3528316 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2424497 USD
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3372964 USD
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
21452 USD
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-155352 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2403045 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3528316 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
-0.024 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
-0.002 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
0.0 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.119 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.020 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.015 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.031 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.009 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.114 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.207 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.323 pure
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0 pure
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0 pure
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0 pure
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9917641 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11626143 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7745734 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
3499 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
3499 USD
CY2017Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
48011 USD
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
96934 USD
CY2015Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
38707 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
388925 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
282850 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1599916 USD
CY2017Q4 xxii Deferred Tax Liabilities Start Up Expenditures
DeferredTaxLiabilitiesStartUpExpenditures
279709 USD
CY2016Q4 xxii Deferred Tax Liabilities Start Up Expenditures
DeferredTaxLiabilitiesStartUpExpenditures
477917 USD
CY2015Q4 xxii Deferred Tax Liabilities Start Up Expenditures
DeferredTaxLiabilitiesStartUpExpenditures
514680 USD
CY2017Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
11760 USD
CY2016Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
139676 USD
CY2015Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
68877 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
69860 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
147070 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4272 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
21423 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9272 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10882516 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12718302 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10127755 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
220888 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
316232 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
227186 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
558760 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
807137 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
767044 USD
CY2017Q4 xxii Deferred Tax Liabilities Other Intangible Assets
DeferredTaxLiabilitiesOtherIntangibleAssets
124953 USD
CY2016Q4 xxii Deferred Tax Liabilities Other Intangible Assets
DeferredTaxLiabilitiesOtherIntangibleAssets
138713 USD
CY2015Q4 xxii Deferred Tax Liabilities Other Intangible Assets
DeferredTaxLiabilitiesOtherIntangibleAssets
80349 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1262082 USD
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1074579 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9977915 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11456220 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6169212 USD
CY2017Q3 xxii Number Of Warrants Exercised
NumberOfWarrantsExercised
6167646 shares
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P8Y11M16D
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0160 pure
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.28
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
750265 USD
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68143284 shares
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19796420 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19432600 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20244771 shares
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
169000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
169000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
169000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
141000 USD
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12088080 shares
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4551420 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3316601 USD
CY2017Q4 us-gaap Defined Benefit Plan Funded Percentage
DefinedBenefitPlanFundedPercentage
0.03 pure
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
98368 USD
CY2016 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
84499 USD
CY2015 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
56208 USD
CY2015 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
144550 USD
CY2016 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
29615 USD
CY2016 xxii Reclassification Of Warrant Liability To Capital In Excess Of Par Value
ReclassificationOfWarrantLiabilityToCapitalInExcessOfParValue
2810000 USD
CY2017 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
157809 USD
CY2016 xxii Warrants Issued In Conjunction With Registered Direct Offering
WarrantsIssuedInConjunctionWithRegisteredDirectOffering
2500000 shares
CY2016 xxii Common Stock Warrants Issued Additional Number
CommonStockWarrantsIssuedAdditionalNumber
2089 shares
CY2017 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7526 USD
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
57648 USD
CY2015 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
57648 USD
CY2017Q4 xxii Warrants Outstanding
WarrantsOutstanding
12088080 shares
CY2015 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
144550 USD
CY2017Q4 xxii Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
5500000 shares
CY2016 xxii Warrants Expired And Unexercised
WarrantsExpiredAndUnexercised
6831115 shares
CY2017 xxii Number Of Warrants Exercised
NumberOfWarrantsExercised
12763238 shares
CY2017 xxii Number Of Warrants Exercised On Cashless Basis
NumberOfWarrantsExercisedOnCashlessBasis
1286277 shares
CY2017 xxii Warrants Expired And Unexercised
WarrantsExpiredAndUnexercised
223814 shares
CY2017 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 37.4pt; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;<b> <i>Reclassifications</i></b> <i>-</i> Certain items in the 2016 and 2015 financial statements have been reclassified to conform to the 2017 classification.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Concentration of Credit Risk</font></i></b> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> -</font></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in financial institutions. Although the cash accounts exceed the federally insured deposit amount, management does not anticipate nonperformance by the financial institutions. Management reviews the financial viability of these institutions on a periodic basis.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of Estimates</font></i></b> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> -</font></b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16634778 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13781921 shares
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1263677 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
214628 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1478305 USD
CY2017 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-1478305 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.461 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0 pure
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
904601 USD
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
47000000 USD
CY2017 xxii Proceeds From Issuance Registered Direct Offering Three
ProceedsFromIssuanceRegisteredDirectOfferingThree
0 USD
CY2016 xxii Proceeds From Issuance Registered Direct Offering Three
ProceedsFromIssuanceRegisteredDirectOfferingThree
4682764 USD
CY2015 xxii Proceeds From Issuance Registered Direct Offering Three
ProceedsFromIssuanceRegisteredDirectOfferingThree
0 USD
CY2017 xxii Proceeds From Issuance Registered Direct Offering Four
ProceedsFromIssuanceRegisteredDirectOfferingFour
0 USD
CY2016 xxii Proceeds From Issuance Registered Direct Offering Four
ProceedsFromIssuanceRegisteredDirectOfferingFour
5091791 USD
CY2015 xxii Proceeds From Issuance Registered Direct Offering Four
ProceedsFromIssuanceRegisteredDirectOfferingFour
0 USD
CY2017 xxii Proceeds From Issuance Registered Direct Offering Five
ProceedsFromIssuanceRegisteredDirectOfferingFive
0 USD
CY2016 xxii Proceeds From Issuance Registered Direct Offering Five
ProceedsFromIssuanceRegisteredDirectOfferingFive
0 USD
CY2015 xxii Proceeds From Issuance Registered Direct Offering Five
ProceedsFromIssuanceRegisteredDirectOfferingFive
5576083 USD
CY2014Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3042846 USD
CY2015Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2898296 USD
CY2016Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
58681 USD
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
216490 USD
CY2017 xxii Deferred Tax Assets Increase Decrease Percent
DeferredTaxAssetsIncreaseDecreasePercent
0.46 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.018 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0 pure
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
232198 USD
CY2017Q4 xxii Litigation Settlement Shares To Be Issued
LitigationSettlementSharesToBeIssued
2077555 shares
CY2017Q4 us-gaap Loss Contingency Receivable
LossContingencyReceivable
18000000 USD

Files In Submission

Name View Source Status
0001144204-18-013354-index-headers.html Edgar Link pending
0001144204-18-013354-index.html Edgar Link pending
0001144204-18-013354.txt Edgar Link pending
0001144204-18-013354-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
graph.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv484508_10k.htm Edgar Link pending
tv484508_ex21-1.htm Edgar Link pending
tv484508_ex23-1.htm Edgar Link pending
tv484508_ex31-1.htm Edgar Link pending
tv484508_ex31-2.htm Edgar Link pending
tv484508_ex32-1.htm Edgar Link pending
xxii-20171231.xml Edgar Link completed
xxii-20171231.xsd Edgar Link pending
xxii-20171231_cal.xml Edgar Link unprocessable
xxii-20171231_def.xml Edgar Link unprocessable
xxii-20171231_lab.xml Edgar Link unprocessable
xxii-20171231_pre.xml Edgar Link unprocessable